Ser12
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser12  -  DRAK2 (human)

Site Information
RFDCRsIsGLLTTTP   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 1851300

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 , 3 , 4 ) , mutation of modification site ( 4 ) , phospho-antibody ( 4 ) , western blotting ( 4 )
Disease tissue studied:
HER2 positive breast cancer ( 1 ) , luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 ) , breast cancer, triple negative ( 1 )
Relevant cell line - cell type - tissue:
B lymphocyte-spleen ( 4 ) , BaF3 ('B lymphocyte, precursor') ( 4 ) , breast ( 1 ) , HEK293T (epithelial) ( 4 ) , Jurkat (T lymphocyte) ( 2 , 3 , 4 ) , splenocyte-spleen ( 4 ) , T lymphocyte-spleen ( 4 )

Upstream Regulation
Treatments:
anti-CD3 ( 4 )

References 

1

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

2

Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7
23749302   Curated Info

3

Mayya V, et al. (2009) Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions. Sci Signal 2, ra46
19690332   Curated Info

4

Friedrich ML, et al. (2007) Modulation of DRAK2 autophosphorylation by antigen receptor signaling in primary lymphocytes. J Biol Chem 282, 4573-84
17182616   Curated Info